Dermata Therapeutics
DRMA
5 hedge funds and large institutions have $463K invested in Dermata Therapeutics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
56% more capital invested
Capital invested by funds: $297K → $463K (+$166K)
12.74% more ownership
Funds ownership: 0.8% → 13.53% (+13%)
50% less funds holding
Funds holding: 10 → 5 (-5)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$300K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.78K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$20.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$16K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$8.61K |
| 4 |
Jones Financial Companies
Des Peres,
Missouri
|
-$7.25K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$644 |
DRMA Hedge Fund Activity: Q3 2025 in Review
5 institutional investors reported a position in Dermata Therapeutics (DRMA) for Q3 2025, worth a combined $463K — up 56% from $297K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DRMA and 0 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, adding an estimated $300K. The largest seller was XTX Topco, exiting entirely with an estimated $20.2K sold.
- 5 institutional investors held Dermata Therapeutics (DRMA) as of Q3 2025, down from 10 in Q2 2025.
- Funds reported $463K of Dermata Therapeutics stock for Q3 2025, up 56% quarter-over-quarter.
- 0 funds opened new Dermata Therapeutics positions in Q3 2025 and 5 closed out, a net change of -5 holders.
- The largest Dermata Therapeutics buyer in Q3 2025 was Armistice Capital, an estimated $300K added.
- The largest Dermata Therapeutics seller in Q3 2025 was XTX Topco, an estimated $20.2K sold.
Based on aggregated 13F filings for Q3 2025.